The Risk of Nephrogenic Systemic Fibrosis in Group II and III Gadolinium-Based Contrast Agents

Can Assoc Radiol J. 2020 Nov;71(4):536. doi: 10.1177/0846537119888408. Epub 2020 Jan 31.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Canada
  • Contrast Media / adverse effects*
  • Gadolinium / adverse effects*
  • Humans
  • Nephrogenic Fibrosing Dermopathy / chemically induced*
  • Nephrogenic Fibrosing Dermopathy / prevention & control*
  • Practice Guidelines as Topic
  • Risk
  • United States

Substances

  • Contrast Media
  • Gadolinium